LEISGUARD TECHNICAL INFORMATION.

Only for Veterinarians or Animal Health professionals.
Due to legal considerations in different countries the content of this site is only available for members of the veterinary profession. By clicking the link below you agree that your profession and your knowledge allow you to access information on veterinary drugs in your country.

Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country.

The information summarizes the current status of our knowledge and may differ from the legally binding, country specific use instructions provided with the product.
Download
Title / Autors / Source
A single-centre, open-label, controlled, randomized clinicaltrial to assess the preventive efficacy of a domperidone-basedtreatment programme against clinical canine leishmaniasisin a high prevalence area. Sabaté, D.; Llinás, J.; Homedes, J.; Sust, M.; Ferrer, L. Preventive Veterinary Medicine 115 (2014) 56–63
Domperidone is an effective treatment for mild cases (Leishvet Stage I) of canine leishmaniosis: a double blind placebo controlled trial. Sabaté, D.; Gómez-Ochoa, P.; Llinás, J.; Homedes, J.; Ferrer, L. Proceedings of the WORLDLEISH5 Congress, Pernambuco, 2013
New Perspectives on Canine Leishmaniosis therapy II: immune potentiating treatments. Ferrer, L. Proceedings of the Bayer Animal Health Symposium WORLDLESIH5, Pernambuco, 2013.
Leisguard® enhances the leishmanicidal activity of canine macrophages. Sabaté, D.; Homedes, J.; Gómez-Ochoa, P. Proceedings of the UNISVET Congress, Napoli, 2013
Rapid stimulatory effect of Leisguard® on the canine innate immune system. Sabaté, D.; Mayós, I.; Cepeda, E; Homedes, J. Proceedings of the SCIVAC Congress, Pisa, 2013
Canine Lesihmaniosis and other vector-born diseases: our current state of knowledge. Roura, X. Proceedings of the SCIVAC Congress, Pisa, 2013
Study of the effect of leisguard® on the efficacy of a standard vaccination schedule in puppies. Salichs, M.; Sabaté, D.; Rodon J.; Homedes J. Proceedings of the SEVC-47th AVEPA Congress, Barcelona, 2012
Clinical efficacy of Leisguard® for the prevention of canine Leishmaniosis in an enemic area with high risk of infection. Sabaté, D.; Llinás, J.; Suay, P.; Homedes, J.; Ferrer, L. Proceedings of the SEVC-47th AVEPA Congress, Barcelona, 2012
Clinical efficacy of a Leisguard®-based program strategically established for the prevention of canine leishmaniosis in endemic areas with low prevalence. Gómez-Ochoa, P.; Sabaté, D.; Homedes, J.; Ferrer, L. Proceedings of the 73º Congresso Internazionale Multisala SCIVAC, Rimini 2012, p. 545
Efficacy of a combined therapy with meglumine antimoniate and domperidone for the treatment of canine leishmaniosis. Lanaro, E. Proceedings of the 73º Congresso Internazionale Multisala SCIVAC, Rimini 2012, p. 531
Use of the nitroblue tetrazolium reduction test for the evaluation of Domperidone effects on the neutrophilic function of healthy dogs. Gómez-Ochoa P, Sabate D, Homedes J, Ferrer L. Vet Immunol Immunopathol 2012 Mar 15;146(1):97-9.
Clinical efficacy of a domperidone-based treatment program for the prevention of canine leishmaniosis. Llinás J, Gómez-Ochoa P, Sabaté D, Homedes J, Ferrer L. Proceedings of the 46th AVEPA-SEVC Congress, 2011.
Efficacy of domperidone for the treatment of mild and moderate cases of canine leishmaniosis: clinical and immunological short-term follow-up. Gómez-Ochoa P, Sabate D, Homedes H, Ferrer L. Proceedings of the 21st ECVIM Congress, 2011; abstract no. Im-0-10
Use of domperidone in the treatment of canine visceral leishmaniasis: A clinical trial. Gómez-Ochoa, P., Castillo, J.A. Gascón, M., Zarate , J.J., Alvarez, F., Couto, C.G. The Veterinary Journal 179 2009 259–26